Colchicine may be of therapeutic benefit in prurigo pigmentosa

Pediatr Dermatol. 2018 May;35(3):e202-e203. doi: 10.1111/pde.13480. Epub 2018 Apr 11.

Abstract

Prurigo pigmentosa (PP) is a rare inflammatory skin disease. Neutrophil-mediated inflammation is considered to be responsible for the etiopathogenesis of PP. We consider that colchicine may be an effective agent in the treatment of PP since it exerts an antiinflammatory effect by inhibiting neutrophil chemotaxis. Further studies are required to verify whether colchicine is an effective treatment option for PP.

Keywords: pharmacology; pruritus; therapy-systemic.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Colchicine / therapeutic use*
  • Female
  • Humans
  • Hyperpigmentation / drug therapy*
  • Hyperpigmentation / etiology
  • Prurigo / drug therapy*
  • Prurigo / etiology
  • Skin / pathology
  • Treatment Outcome
  • Tubulin Modulators / therapeutic use*

Substances

  • Tubulin Modulators
  • Colchicine